Loading...
01/11 03:18
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. While there is growth in pediatrics and improved reimbursement for heart failure, the overall financial performance is concerning. Revenue declined by 21% due to a product back order, and margins fell significantly. The termination of the REVERSE-HF trial and increased net losses further add to the negative sentiment. Despite the resolution of the sterilization issue and potential in pediatrics, the financial challenges and operational risks outweigh the positives, leading to a negative outlook for the stock.
Revenue for Q2 2025 $1.7 million, a year-over-year decline of 21%. The decline was primarily due to an industry-wide issue with the sterilization vendor, resulting in a temporary back order of approximately $400,000 in revenue.
Pediatric Revenue Increased by 23% compared to Q2 2024. This growth reflects strong demand from established hospital customers and interest from new centers.
Heart Failure Revenue Declined by 53% compared to Q2 2024. The decline was significantly impacted by the temporary back order.
Critical Care Revenue Declined by 35% compared to Q2 2024. The decline was significantly impacted by the temporary back order.
Gross Margin 55.5% compared to 67.2% in Q2 2024. The decrease was largely due to under-absorption of fixed overhead because of lower production volumes.
Selling, General and Administrative Expenses $3.2 million, flat compared to Q2 2024.
Research and Development Expense $675,000, a slight increase compared to $558,000 in Q2 2024.
Total Operating Expenses $3.9 million, a 2% increase over Q2 2024.
Operating Loss $2.9 million, compared to $2.3 million in Q2 2024. The increase reflects higher operating expenses.
Net Loss Attributable to Common Shareholders $12.6 million, or a loss of $60.99 per share, compared to $7.7 million, or a loss of $791.82 per share in Q2 2024. The increase in net loss is due to higher operating losses and other financial factors.
Cash and Cash Equivalents $4.5 million at the end of Q2 2025, with no debt. The recent $5 million gross capital raise bolstered the financial position.
Aquadex: Continued strong demand in pediatrics and increasing adoption in critical care. Focused on outpatient heart failure opportunities, refining support tools, and enhancing site engagement programs.
Pediatrics: Revenue increased by 23% compared to Q2 2024, driven by strong demand and interest from new centers.
Critical Care: Increasing adoption as accounts move from trialing to consistent practice, particularly in post-cardiac surgery fluid management.
Outpatient Heart Failure: Efforts centered on outpatient clinics, showing value as a cost-efficient alternative.
Manufacturing Transition: Transitioning to KDI Precision Manufacturing by October, expected to result in operational efficiencies and cost savings over the next 12 months.
REVERSE-HF Clinical Trial Termination: Terminated the trial to reallocate $4 million to higher-impact growth areas, not due to device performance or safety concerns.
Growth Strategy: Focused on cardiac surgery, pediatrics, and outpatient heart failure. Expanding reimbursement and clinical need for broader access to ultrafiltration.
Revenue decline: Revenue for the second quarter was $1.7 million, a year-over-year decline of 21%, primarily driven by a temporary product back order due to an industry-wide issue with the sterilization vendor.
Product back order: The temporary back order caused approximately $400,000 in lost revenue and significantly impacted heart failure and critical care revenue, which declined by 53% and 35%, respectively.
Gross margin decline: Gross margin for the quarter dropped to 55.5% from 67.2% in Q2 2024, largely due to under-absorption of fixed overhead because of lower production volumes.
Operating loss: Operating loss for Q2 was $2.9 million, compared to $2.3 million in Q2 2024, reflecting increased operational challenges.
Net loss: Net loss attributable to common shareholders was $12.6 million, significantly higher than the $7.7 million loss in Q2 2024, indicating worsening financial performance.
Manufacturing transition risks: The planned transition to KDI Precision Manufacturing by October could pose risks related to operational disruptions or delays, despite expected cost savings.
Termination of REVERSE-HF trial: The termination of the REVERSE-HF clinical trial reallocates $4 million but may limit future evidence-building for inpatient heart failure, potentially impacting strategic opportunities.
Challenges in outpatient heart failure scaling: Scaling outpatient heart failure programs faces challenges such as staffing, space, and operational complexities, which could hinder broader adoption of Aquadex.
Transition to KDI Precision Manufacturing: The company plans to transition its manufacturing to KDI Precision Manufacturing by October, expecting meaningful operational efficiencies and cost savings over the next 12 months.
Termination of REVERSE-HF Clinical Trial: The company terminated the REVERSE-HF clinical trial to reallocate approximately $4 million toward higher impact growth areas, focusing on cardiac surgery, pediatrics, and outpatient heart failure.
Cardiac Surgery Growth Strategy: The company aims to expand the use of Aquadex in managing postoperative fluid overload and protecting renal function in cardiac surgery patients.
Pediatrics Growth Strategy: Aquadex remains a viable fluid management option for children with little to no kidney function, and the company plans to continue focusing on this segment.
Outpatient Heart Failure Growth Strategy: The company sees expanded reimbursement and clinical need paving the way for broader access to ultrafiltration in outpatient heart failure programs.
Financial Priorities: The company is focused on progressing towards being cash flow positive and delivering on commercial targets in pediatrics and cardiac surgery.
The selected topic was not discussed during the call.
The earnings call reveals several challenges: a 6% revenue decline, reduced gross margins, increased operating expenses, and a higher operating loss. Despite some positive aspects like sequential revenue growth and a focus on U.S. market expansion, the termination of international operations and dependency on the U.S. market pose risks. The cash position is limited, and manufacturing transition risks exist. With no new partnerships or positive shareholder return plans discussed, the overall sentiment is negative, likely leading to a -2% to -8% stock price movement.
The earnings call presents a mixed picture. While there is growth in pediatrics and improved reimbursement for heart failure, the overall financial performance is concerning. Revenue declined by 21% due to a product back order, and margins fell significantly. The termination of the REVERSE-HF trial and increased net losses further add to the negative sentiment. Despite the resolution of the sterilization issue and potential in pediatrics, the financial challenges and operational risks outweigh the positives, leading to a negative outlook for the stock.
The earnings call reveals mixed signals. While there are positive developments like increased reimbursement rates and outpatient market entry, there are concerns about declining international sales, margin reduction, and customer dependency risks. The Q&A section highlighted some unresolved issues, such as the lack of clarity on revenue drops and vague timelines for clinical trials. Despite financial improvements in operating loss and expenses, the absence of a share repurchase program and manufacturing challenges temper expectations. Overall, these factors suggest a neutral impact on the stock price over the next two weeks.
The earnings call presents mixed signals. Positive factors include new account wins, outpatient market entry, increased reimbursement rates, and operating loss improvements. However, these are offset by declining international sales, customer dependency risks, reduced gross margins, and lack of clear guidance in the Q&A. The absence of a share repurchase program and a decrease in cash position further contribute to a neutral outlook. Given these factors, the stock is likely to remain stable within a -2% to 2% range over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
